Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 123 participants.
Also called NCT04976283
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 123 participants
- Sponsor
- Registry
-
NCT04976283
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Pakistan
- Registry status
- Unknown status
Technical summary
Registry record NCT04976283. Randomized; no masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2023-05-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
- Condition
- Diabetes Mellitus, Type 2
- Condition
- NASH - Nonalcoholic Steatohepatitis
- Condition
- NAFLD
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Pioglitazone + Empagliflozin
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct04976283- Content hash
bff838853283708e35e94f4d8aecff19c85bfe4775bce034b2a37d12d3d75451